| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total operating expenses | 24,869,251 | - |
| Interest income | 992,582 | - |
| Interest expense | 4,225,737 | - |
| Benefit from income taxes | -1,169,820 | - |
| Net loss | -26,932,586 | -17,923,175 |
| Stock-based compensation expense | 2,948,396 | 1,701,911 |
| Issuance of shares in consulting agreements | 203,501 | 203,501 |
| Amortization of debt discount | 1,079,427 | 1,386,606 |
| Loss on retirement of debt | -752,838 | - |
| Depreciation expense | 16,377 | 10,918 |
| Finance lease depreciation expense | 29,010 | 19,340 |
| Prepaid expenses and other assets | 4,883,470 | 4,963,760 |
| Accounts payable | 3,496,060 | 2,812,566 |
| Accrued expenses | -758,980 | -1,381,286 |
| Net cash used in operating activities | -24,049,427 | -18,133,379 |
| Purchase of equipment | 0 | 0 |
| Net cash used in investing activities | 0 | 0 |
| Proceeds from issuance of pre-funded warrants | 1,009,969 | 1,009,969 |
| Proceeds from issuance of warrants | 2,150,771 | 2,150,771 |
| Proceeds from exercise of pre-funded warrants | 94 | 94 |
| Proceeds from exercise of stock options | 0 | 0 |
| Payments of finance lease obligations | 45,313 | 29,862 |
| Loan principal payments | 5,166,667 | 4,166,667 |
| Loan repayment | 18,645,833 | 18,645,833 |
| Net proceeds from issuance of loan | 19,237,884 | 19,237,880 |
| Proceeds from issuance of common stock from the sales agreement, net | 3,023,409 | 1,766,757 |
| Proceeds from issuance of common stock, net of issuance costs | 6,994,174 | 6,994,174 |
| Net cash provided by financing activities | 8,558,488 | 8,317,283 |
| Net decrease in cash and cash equivalents | -15,490,939 | -9,816,096 |
| Cash and cash equivalents at beginning of period | 41,689,591 | - |
| Cash and cash equivalents at end of period | 26,198,652 | - |
PDS Biotechnology Corp (PDSB)
PDS Biotechnology Corp (PDSB)